HMPL-523: Phase I started

Hutchison China MediTech began an open-label, Australian Phase I trial to evaluate 100, 200, 400, 600 and 800 mg oral HMPL-523 once daily in 28-day cycles in up to 47 patients. The dose-escalation par...